12.12.2012 Views

ISBN: 978-83-60043-10-3 - eurobic9

ISBN: 978-83-60043-10-3 - eurobic9

ISBN: 978-83-60043-10-3 - eurobic9

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Eurobic9, 2-6 September, 2008, Wrocław, Poland<br />

P200. Improving Platinum Chemotherapy Through Controlled and<br />

Targeted Drug Delivery<br />

N. Wheate<br />

Strathclyde Institute of Pharmacy and Biomedical S,University of Strathclyde,27 Taylor Street,G40NR,<br />

Glasgow,United Kingdom<br />

e-mail: nial.wheate@strath.ac.uk<br />

Cisplatin, carboplatin and oxaliplatin are the only three platinum based drugs with wide approval for the<br />

treatment of human cancers [1]. Whilst several new drugs are in various stages of clinical trials including<br />

satraplatin, picoplatin and multinuclear drugs [1], the biggest advances in the coming decade will come from the<br />

development of controlled and targeted drug delivery systems. Over the last 5 years our work has focussed on<br />

macromolecules which can encapsulate mono- and multinuclear platinum complexes and platinum based DNA<br />

intercalators [2-3]. This includes cyclodextrins, calixarenes, cucurbiturils and PAMAM dendrimers. Many of<br />

these macromolecules are able to prevent drug degradation by thiol peptides and proteins and can be used to tune<br />

the cytotoxicity and toxicity of the drugs. In vivo animal trials also demonstrated that one drug delivery vehicle,<br />

cucurbituril was able to nearly double the maximum tolerated dose of a multinuclear platinum drug. The first<br />

phase of our research is nearly complete and we are now examining two-fold drug encapsulation and suitable<br />

targeting groups. In the end, the goal of our research is the development of a targeted platinum drug delivery<br />

system that can specifically recognise and bind cancer cells, thus eliminating many of the side-effect of platinum<br />

drugs from that arise from non-specific cellular attack, and improve drug efficacy.<br />

References:<br />

[1]L. Kelland. The resurgence of platinum-based cancer chemotherapy, Nature Reviews Cancer, 2007, 7, 573-<br />

584.<br />

[2] N. J. Wheate, D. P. Buck, A. I. Day, J. G. Collins, Cucurbit[n]uril binding of platinum anticancer complexes,<br />

Dalton Transactions, 2006, 451-458.<br />

[3] S. Kemp, N. J. Wheate, S. Wang, J. G. Collins, S. F. Ralph, A. I. Day, V. J. Higgins, J. R. Aldrich-Wright,<br />

Encapsulation of platinum(II)-based DNA intercalators within cucurbit[6,7,8]urils, Dalton Transactions, 2007,<br />

12, 969-979.<br />

_____________________________________________________________________<br />

319

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!